Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
2.
Am J Emerg Med ; 33(7): 899-903, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25936477

ABSTRACT

STUDY OBJECTIVE: We describe emergency physician staffing, capabilities, and academic practices in US Veterans Health Administration (VHA) emergency departments (EDs). METHODS: As part of an ongoing process improvement effort for the VHA emergency care system, VHA-wide surveys are conducted among ED medical directors every 3 years. Web-based surveys of VHA ED directors were conducted in 2013 on clinical operations and academic program development. We describe the results from the 2013 survey. When available, we compare responses with the previously administered survey from 2010. RESULTS: A total of 118 of 118 ED directors filled out the survey in 2013 (100% response rate). Respondents reported that 45.5% of VHA emergency physicians are board certified in emergency medicine, and 95% spend most their time in direct patient care. Clinical care is also provided by part-time (<0.5 full-time employee equivalent) emergency physicians in 59.3% of EDs. More than half of EDs (57%) provide on-site tissue plasminogen activator for acute ischemic stroke patients, and only 39% can administer tissue plasminogen activator 24 hours per day, 7 days per week. Less than half (48.3%) of EDs have emergency Obstetrics and Gynecology consultation availability. Most VHA EDs (78.8%) have a university affiliation, but only 21.5% participated in the respective academic emergency medicine program. CONCLUSIONS: Veterans Health Administration emergency physicians have primarily clinical responsibilities, and less than half have formal emergency medicine board certification. Despite most VHA EDs having university affiliations, traditional academic activities (eg, teaching and research) are performed in only 1 in 3 VHA EDs. Less than half of VHA EDs have availability of consulting services, including advanced stroke care and women's health.


Subject(s)
Emergency Medicine/statistics & numerical data , Emergency Service, Hospital/statistics & numerical data , Hospitals, University/statistics & numerical data , Hospitals, Veterans/statistics & numerical data , Personnel Staffing and Scheduling/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Cross-Sectional Studies , Data Collection , Faculty, Medical/statistics & numerical data , Fibrinolytic Agents/supply & distribution , Gynecology , Hospitals, University/organization & administration , Hospitals, Veterans/organization & administration , Humans , Obstetrics , Stroke/drug therapy , Tissue Plasminogen Activator/supply & distribution , United States , United States Department of Veterans Affairs , Workforce
3.
Ann N Y Acad Sci ; 1268: 57-62, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22994222

ABSTRACT

The past 15 years have witnessed significant strides in the management of acute stroke. The most significant advance, reperfusion therapy, has changed relatively little, but the integrated healthcare systems-stroke systems-established to effectively and safely administer stroke treatments have evolved greatly. Driving change is the understanding that "time is brain." Data are compelling that the likelihood of improvement is directly tied to time of reperfusion. Regional stroke systems of care ensure patients arrive at the most appropriate stroke-capable hospital in which intrahospital systems have been created to process the potential stroke patient as quickly as possible. The hospital-based systems are comprised of prehospital care providers, emergency department physicians and nurses, stroke team members, and critical ancillary services such as neuroimaging and laboratory. Given their complexity, these systems of care require maintenance. Through teamwork and ownership of the process, more patients will be saved from potential death and long-term disability.


Subject(s)
Brain Ischemia/therapy , Emergency Service, Hospital/organization & administration , Quality Improvement , Acute Disease , Brain Ischemia/diagnosis , Brain Ischemia/drug therapy , Delivery of Health Care, Integrated , Efficiency , Emergency Medical Service Communication Systems , Emergency Medical Services , Emergency Service, Hospital/statistics & numerical data , Facility Design and Construction , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/supply & distribution , Fibrinolytic Agents/therapeutic use , Hospital Units , Humans , Medication Systems, Hospital , Neuroimaging , Patient Admission , Patient Care Team , Patient Transfer , Recombinant Proteins/administration & dosage , Recombinant Proteins/supply & distribution , Recombinant Proteins/therapeutic use , Task Performance and Analysis , Telemedicine , Thrombolytic Therapy , Time Factors , Tissue Plasminogen Activator/administration & dosage , Tissue Plasminogen Activator/supply & distribution , Tissue Plasminogen Activator/therapeutic use , Transportation of Patients/organization & administration
4.
Cerebrovasc Dis ; 31(6): 559-65, 2011.
Article in English | MEDLINE | ID: mdl-21487220

ABSTRACT

BACKGROUND: Intravenous (IV) alteplase is not currently recommended in octogenarian patients, and the benefit/risk ratio of endovascular (intra-arterial, IA) therapy remains to be determined. The aim of this study was to determine the impact of a combined IV-IA approach in octogenarians. METHODS: From a single-centre interventional study, we report age-specific outcomes of patients treated by a combined IV-IA thrombolytic approach. Patients ≥80 years with documented arterial occlusion treated by conventional IV thrombolysis constituted the control group. RESULTS: Among 84 patients treated by the IV-IA approach, those ≥80 years (n = 25) had a similar rate of early neurological improvement to that of patients <80 years, whereas the 90-day favourable outcome rate was lower in octogenarians (adjusted odds ratio, OR, 0.21; 95% confidence interval, CI, 0.06-0.75). No difference in symptomatic intracranial haemorrhage was observed whereas a higher rate of 90-day mortality (adjusted OR, 3.27; 95% CI, 0.76-14.14) and asymptomatic intracranial haemorrhage (adjusted OR, 6.39; 95% CI, 1.54-26.63) were found in patients ≥80 years old. Among octogenarians, and compared to IV-thrombolysis-treated patients (n = 24), patients treated by the IV-IA approach had a higher rate of recanalization (76 vs. 33%, p = 0.003) associated with increased early neurological improvement (32 vs. 8%, p = 0.07). Although there was a higher rate of asymptomatic intracranial haemorrhage (44 vs. 8%, p = 0.005) observed in the IV-IA group, no difference existed in symptomatic intracranial haemorrhage rates and 90-day favourable outcome. CONCLUSION: The IV-IA approach in octogenarians was associated with lower efficacy at 3 months and higher mortality and asymptomatic haemorrhagic complications than in patients <80 years old. Definite recommendations cannot be given, but an endovascular approach may cause more harm than positive effects in patients over 80 years and should not be considered outside an approved protocol.


Subject(s)
Brain Ischemia/drug therapy , Fibrinolytic Agents/administration & dosage , Stroke/drug therapy , Thrombolytic Therapy/methods , Tissue Plasminogen Activator/supply & distribution , Acute Disease , Adult , Age Factors , Aged, 80 and over , Brain Ischemia/mortality , Female , Humans , Injections, Intra-Arterial , Injections, Intravenous , Male , Middle Aged , Registries/statistics & numerical data , Risk Factors , Stroke/mortality , Thrombolytic Therapy/statistics & numerical data , Treatment Outcome
5.
Tech Vasc Interv Radiol ; 4(2): 127-30, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11981800

ABSTRACT

Dosing of thrombolytic agents for restoration of flow to thrombotically occluded central venous catheters has been empiric. The lowest effective dose of any agent is not known. Given that none of the dosing regimens in current use has ever been found to be toxic, this is probably not a major clinical problem as long as the regimen is highly effective. Thrombolytic regimens differ in the type of drug, dose of drug, method of administration (injection versus prolonged infusion), and duration of administration. All of these variables are important in determining the efficacy, and possibly the toxicity, of a regimen. Active research is being conducted to determine the most effective ways of using the expanding number of thrombolytic medications that are now, or soon may be, on the market.


Subject(s)
Catheterization, Central Venous/adverse effects , Thrombolytic Therapy , Thrombosis/drug therapy , Thrombosis/etiology , Dose-Response Relationship, Drug , Equipment Failure , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/supply & distribution , Humans , Tissue Plasminogen Activator/administration & dosage , Tissue Plasminogen Activator/supply & distribution , United States , United States Food and Drug Administration , Urokinase-Type Plasminogen Activator/administration & dosage , Urokinase-Type Plasminogen Activator/supply & distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...